MARK T. GOULET, Ph.D.
Executive Director,
Drug Discovery & Optimization

Dr. Goulet received a B.S. degree in chemistry from the University of Michigan and a Ph.D. in chemistry from Yale University.  He joined Merck in 1987 and worked within the Medicinal Chemistry department at Rahway in the areas of immunoregulation, endocrinology, obesity and atherosclerosis.  In 2004 he moved to Boston to become Head of Chemistry at the opening of this research facility.

Key Publications, 2006 – Present
Lin, L.S.; Lanza, T.J.; Jewell. J.P.; Liu, P.; Shah, S.K.; Qi, H.; Tong, X.; Wang, J.; Xu, S.S.; Fong, T.M.; Shen, C.-P.; Lao, J.; Xiao, J.C.; Shearman, L.P.; Stribling, D.S.; Rosko, K.; Strack, A., Marsh, D.J.; Feng, Y.; Kumar, S.; Samuel, K.; Yin, W.; Van der ploeg, L.H.T.; Goulet, M.T.; Hagmann, W.K. "Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2{[5-(trifluoromethyl)pyridine-2-yl]oxy}propanamide (MK-0364), a Novel Acyclic Cannabinoid-1 Receptor Inverse Agonist for the treatment of Obesity " J. Med. Chem., 2006, 49, 7584-7587.

Burns, H.D.; Van Laere, K.; Sanabria-Bohorquez, S.; Hamill, T.G.; Bormans, G.; Eng, W.-s.; Gibson, R.; Ryan, C.; Connolly, C.; Patel, S.; Krause, S.; Vanko, A.; Van Hecken, A.; Dupont, P.; De Lepeleire, I.; Rothenberg, P.; Stoch, S. A.; Cote, J.; Hagmann, W.K.; Jewell, J.P.; Lin, L.S.; Liu, P.; Goulet, M.T.; Gottesdiener, K.; Wagner, J.A.; deHoon, J.; Mortelmans, L.; Fong, T.M.; Hargreaves, R.J. "[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor " PNAS, 2007, 104, 9800-9805.

Fong, T.M.; Guan, X.-M.; Marsh, D.J.; Shen, C.-P.; Stribling, S.; Rosko, K.M.; Lao, J.; Yu, H.; Feng, Y.; Xiao, J.C.; Van dr Ploeg, L.H.T.; Goulet, M.T.; Hagmann, W.K.; Lin, L.S.; Lanza, T.J.; Jewell, J.P.; Liu, P.; Shah, S.K.; Qi, H.; Tong, X.; Wang, J.; Xu, S.S.; Francis, B.; Strack, A.M.; MacIntyre, D.E.; Shearman, L.P. "Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2{[5-(trifluoromethyl)pyridine-2-yl]oxy}propanamide (MK-0364), in Rodents " J. Pharmacol. Exp. Ther., 2007, 321, 1013-1022.

Liu, P.; Lin, L.S.; Hamill. T.G.; Jewell, J.P.; Lanza, TY.J.; Gibson, R.E.; Krause, S.M.; Ryan, C.; Eng, W.; Sanabria, S.; Tong, X.; Wang, J.; Levorse, D.A.; Owens, K.A.; Fong, T.M.; Shen, C.-P.; Lao, J.; Kumar, S.; Yin, W.; Payack, J.F.; Springfield, S.A.; Hargreaves, R.; Burns, H.D.; Goulet, M.T.; Hagmann, W.H  "Discovery of N-{(1S,2S)-2-(3-Cyanophenyl)-3-[4-(2-[18F]fluoroethoxy)phenyl]-1methylpropyl}-2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a Cannabinoid-1 Receptor Positron Emission Tomography Tracer Suitable for Clinical Use " J. Med. Chem, 2007, 50, 3427-3430.

Guo, L.; Ye, Z.; Ujjainwalla, F.; Sings, H.L.; Sebhat, I.K.; Huber, J.; Weinberg, D.H.; Tang, R.; MacNeil, T.; Tamvakopoulos, C.; Peng, Q.; MacIntyre, E.; Van der Ploeg, L.H.T.; Goulet, M.T.; Wyvratt, M.J.; Nargund, R.P.  "Synthesis and SAR of Potent and Orally Bioavailable tert-Butylpyrrolidine Archetype Derived Melanocortin Subtype-4 Receptor Modulators "  Bioorg. Med. Chem. Lett.., 2008, 18, 3242-3247.